A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer

被引：0
|
作者：
Takaaki Arigami
Daisuke Matsushita
Keishi Okubo
Masataka Shimonosono
Ken Sasaki
Yusuke Tsuruda
Yoshiaki Kita
Kan Tanabe
Shinichiro Mori
Shigehiro Yanagita
Yoshikazu Uenosono
Akihiro Nakajo
Hiroshi Kurahara
Takao Ohtsuka
机构：
[1] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Onco
[2] Kagoshima University Graduate School of Medical and Dental Sciences,Biological Surgery
来源：
Surgery Today | 2022年 / 52卷
关键词：
Gastric cancer; Conversion surgery; Prognosis; Trastuzumab; HER2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1721 / 1730
页数：9
相关论文
共 50 条
  • [41] Trastuzumab Pharmacokinetics Influenced by Extent Human Epidermal Growth Factor Receptor 2-Positive Tumor Load
    Munnink, Thijs H. Oude
    Dijkers, Eli C.
    Netters, Sabine J.
    Lub-de Hooge, Marjolijn N.
    Brouwers, Adrienne H.
    Haasjes, Janny G.
    Schroder, Carolina P.
    de Vries, Elisabeth G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : E355 - E356
  • [42] Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
    Perez, Edith A.
    Barrios, Carlos
    Eiermann, Wolfgang
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pierfranco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Burris, Howard A., III
    Petersen, Jennifer A.
    De Haas, Sanne
    Hoersch, Silke
    Patre, Monika
    Ellis, Paul Anthony
    CANCER, 2019, 125 (22) : 3974 - 3984
  • [43] Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model
    Harada, Suguru
    Yanagisawa, Mieko
    Kaneko, Saori
    Yorozu, Keigo
    Yamamoto, Kaname
    Moriya, Yoichiro
    Harada, Naoki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 987 - 994
  • [44] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
    Naoki Hayashi
    Naoki Niikura
    Hideko Yamauchi
    Seigo Nakamura
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2013, 137 : 523 - 531
  • [45] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
    Hayashi, Naoki
    Niikura, Naoki
    Yamauchi, Hideko
    Nakamura, Seigo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 523 - 531
  • [46] Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Shay, Rebecca C.
    Diamond, Jennifer R.
    Kagihara, Jodi A.
    Sams, Sharon B.
    JOURNAL OF BREAST CANCER, 2021, 24 (01) : 106 - 116
  • [47] Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Isakoff, Steven J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 351 - 354
  • [48] Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
    Ohzawa, Hideyuki
    Sakatani, Takashi
    Niki, Toshiro
    Yasuda, Yoshikazu
    Hozumi, Yasuo
    BREAST CANCER, 2014, 21 (05) : 563 - 570
  • [49] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5278 - 5286
  • [50] Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis
    Yoshihara, Kazutaka
    Kobayashi, Yoshimasa
    Endo, Seiko
    Fukae, Masato
    Hennig, Stefanie
    Kastrissios, Helen
    Kamiyama, Emi
    Garimella, Tushar
    Abutarif, Malaz
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (11): : 1232 - 1243
12345